Found: 8
Select item for more details and to access through your institution.
The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab‐containing line of therapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E117, doi. 10.1002/ajh.26449
- By:
- Publication type:
- Article
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 2, p. 99, doi. 10.1111/ejh.13707
- By:
- Publication type:
- Article
The real-world outcomes of multiple myeloma patients treated with daratumumab.
- Published in:
- PLoS ONE, 2021, v. 16, n. 10, p. 1, doi. 10.1371/journal.pone.0258487
- By:
- Publication type:
- Article
The clinical course of multiple myeloma in the era of novel agents: a retrospective, single-center, real-world study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e281, doi. 10.1016/j.clml.2019.09.463
- By:
- Publication type:
- Article
Incidence and clinical characteristics of multiple myeloma with low M-protein levels and normal values of hemoglobin, creatinine, calcium, and serum free light chain ratio.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 521, doi. 10.1002/hon.2906
- By:
- Publication type:
- Article
Nationwide implementation of lenalidomide maintenance in multiple myeloma: A retrospective, real‐world study.
- Published in:
- EJHaem, 2024, v. 5, n. 2, p. 316, doi. 10.1002/jha2.881
- By:
- Publication type:
- Article
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 1006, doi. 10.1002/jha2.774
- By:
- Publication type:
- Article